Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating foliglurax (PXT002331) for reducing motor complications from levodopa in Parkinson disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PXT002331 (foliglurax)

Snippet

Sponsor: Prexton Therapeutics | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED